Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 288

1.

Multiple oral Candida infections in patients with Sjogren's syndrome -- prevalence and clinical and drug susceptibility profiles.

Yan Z, Young AL, Hua H, Xu Y.

J Rheumatol. 2011 Nov;38(11):2428-31. doi: 10.3899/jrheum.100819. Epub 2011 Aug 15.

PMID:
21844143
2.

Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients.

Chavanet P, Lopez J, Grappin M, Bonnin A, Duong M, Waldner A, Buisson M, Camerlynck P, Portier H.

AIDS. 1994 Jul;8(7):945-50.

PMID:
7946104
3.

Oral Candida isolates among HIV-infected subjects in Nigeria.

Nweze EI, Ogbonnaya UL.

J Microbiol Immunol Infect. 2011 Jun;44(3):172-7. doi: 10.1016/j.jmii.2011.01.028. Epub 2011 Jan 20.

4.
5.

Efficacy of fluconazole and itraconazole in the treatment of oral candidiasis in HIV patients.

Menon T, Umamaheswari K, Kumarasamy N, Solomon S, Thyagarajan SP.

Acta Trop. 2001 Oct 22;80(2):151-4.

PMID:
11600094
6.
7.

Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.

Belazi M, Velegraki A, Koussidou-Eremondi T, Andreadis D, Hini S, Arsenis G, Eliopoulou C, Destouni E, Antoniades D.

Oral Microbiol Immunol. 2004 Dec;19(6):347-51.

PMID:
15491459
8.

[Neonatal Candida infections and the antifungal susceptibilities of the related Candida species].

Altuncu E, Bilgen H, Cerikçioğlu N, Ilki A, Ulger N, Bakır M, Akman I, Ozek E.

Mikrobiyol Bul. 2010 Oct;44(4):593-603. Turkish.

PMID:
21063972
10.

Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients.

Wong-Beringera A, Hindler J, Brankovic L, Muehlbauer L, Steele-Moore L.

Diagn Microbiol Infect Dis. 2001 Jan;39(1):25-31.

PMID:
11173188
11.

Prevalence and antifungal susceptibility of yeasts obtained from the oral cavity of elderly individuals.

de Resende MA, de Sousa LV, de Oliveira RC, Koga-Ito CY, Lyon JP.

Mycopathologia. 2006 Jul;162(1):39-44.

PMID:
16830190
12.

In vitro susceptibility of oral Candida to seven antifungal agents.

Kuriyama T, Williams DW, Bagg J, Coulter WA, Ready D, Lewis MA.

Oral Microbiol Immunol. 2005 Dec;20(6):349-53.

PMID:
16238594
13.

Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.

Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, Han XY, Rolston KV, Safdar A, Raad II, Kontoyiannis DP.

Medicine (Baltimore). 2003 Sep;82(5):309-21.

14.

Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons.

Sánchez-Vargas LO, Ortiz-López NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gaitán-Cepeda LA, Quindós G.

Rev Iberoam Micol. 2005 Jun;22(2):83-92.

15.

Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.

Tumbarello M, Caldarola G, Tacconelli E, Morace G, Posteraro B, Cauda R, Ortona L.

J Antimicrob Chemother. 1996 Oct;38(4):691-9.

PMID:
8937963
16.
17.

Prevalence and antifungal resistance profile of Candida spp. oral isolates from patients with type 1 and 2 diabetes mellitus.

Bremenkamp RM, Caris AR, Jorge AO, Back-Brito GN, Mota AJ, Balducci I, Brighenti FL, Koga-Ito CY.

Arch Oral Biol. 2011 Jun;56(6):549-55. doi: 10.1016/j.archoralbio.2010.11.018. Epub 2010 Dec 22.

PMID:
21183157
18.

Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure.

Milan EP, Burattini MN, Kallás EG, Fischmann O, Costa PR, Colombo AL.

Diagn Microbiol Infect Dis. 1998 Nov;32(3):211-6.

PMID:
9884838
19.

Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.

Capoor MR, Nair D, Deb M, Verma PK, Srivastava L, Aggarwal P.

Jpn J Infect Dis. 2005 Dec;58(6):344-8.

20.

Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.

Johnson EM, Warnock DW, Luker J, Porter SR, Scully C.

J Antimicrob Chemother. 1995 Jan;35(1):103-14.

PMID:
7768758

Supplemental Content

Support Center